Daraxonrasib doubles survival rates in pancreatic cancer trials

The experimental drug daraxonrasib has demonstrated the ability to nearly double survival rates in patients with metastatic pancreatic cancer. In a Phase 3 clinical trial, patients receiving the oral medication achieved a median overall survival of 13.2 months, compared to 6.6 months for those receiving standard chemotherapy. Additionally, the 12-month survival rate was 53.3% for the daraxonrasib group, significantly higher than the 18.7% observed in the chemotherapy group.

Daraxonrasib functions as a molecular inhibitor targeting RAS G12 mutations, which are present in approximately 90% of pancreatic tumors. By blocking these specific mutations, the drug slows the uncontrolled cell growth signals that drive the cancer.

Under a special FDA access program, the treatment is becoming available to selected patients while the formal approval process continues. In the United States, Intermountain Health clinics across Utah, Colorado, and Montana are facilitating access, with several patients already awaiting initial deliveries.